Hickman Richard A, Yu Hui, Li Jianhong, Kong Max, Shah Rajal B, Zhou Ming, Melamed Jonathan, Deng Fang-Ming
*Department of Pathology and Urology, New York University Langone Medical Center, New York, NY †Miraca Life Sciences, Dallas, TX.
Am J Surg Pathol. 2017 Apr;41(4):550-556. doi: 10.1097/PAS.0000000000000794.
Atypical intraductal cribriform proliferations of the prostate (AIP) are loose cribriform proliferations of luminal cells that exhibit greater architectural complexity and/or nuclear atypia than high-grade prostatic intraepithelial neoplasia (HGPIN), but lack the diagnostic criteria for intraductal carcinoma (IDC). The significance of AIP has not been formally established. We compared the clinical, morphologic, and immunohistochemical characteristics of AIP with classic IDC in 310 radical prostatectomy specimens that were received over an 18-month period. Of the 310 cases, 46 cases had AIP only (n=10), IDC only (n=6), or AIP coexisting with IDC (n=30). The ERG status of all 46 AIP/IDC cases was identical to the nearby acinar carcinoma, contrasted to just 3 cases of HGPIN (7%, P<0.01). The degree of uniform phosphatase and tensin homolog (PTEN) loss in 34 selected cases was identical in AIP and IDC (66.7%). No foci of HGPIN showed uniform PTEN loss; there was only 38% concordance of PTEN expression pattern between HGPIN and the nearby acinar carcinoma, unlike AIP and IDC (77% and 81%, respectively, P<0.01). AIP-associated and/or IDC-associated carcinoma (n=46) showed a higher stage and grade compared with acinar-only carcinoma (n=264, P<0.01). AIP-associated carcinoma had similar clinicopathologic features as IDC-associated carcinoma, including preoperative prostate-specific antigen, Gleason score, extraprostatic extension, seminal vesicle invasion, and lymph node metastasis (n=36, P>0.05). In conclusion, AIP shares similar ERG/PTEN immunoprofiles and exhibits similar clinical behavior as IDC, warranting immediate repeat biopsy when AIP is identified on biopsy, as is recommended in the most recent WHO Classification of Tumours of the Urinary System and Male Genital Organs, 2016.
前列腺非典型导管筛状增生(AIP)是一种管腔细胞的疏松筛状增生,与高级别前列腺上皮内瘤变(HGPIN)相比,其结构复杂性和/或核异型性更高,但缺乏导管癌(IDC)的诊断标准。AIP的意义尚未得到正式确立。我们在18个月内接收的310例根治性前列腺切除标本中,比较了AIP与经典IDC的临床、形态学和免疫组化特征。在这310例病例中,46例仅患有AIP(n = 10)、仅患有IDC(n = 6)或AIP与IDC共存(n = 30)。所有46例AIP/IDC病例的ERG状态与附近的腺泡癌相同,相比之下,仅有3例HGPIN(7%,P<0.01)如此。在34例选定病例中,AIP和IDC中磷酸酶和张力蛋白同源物(PTEN)一致缺失的程度相同(66.7%)。没有HGPIN灶显示PTEN一致缺失;HGPIN与附近腺泡癌之间PTEN表达模式的一致性仅为38%,与AIP和IDC不同(分别为77%和81%,P<0.01)。与仅腺泡癌(n = 264)相比,AIP相关和/或IDC相关癌(n = 46)的分期和分级更高(P<0.01)。AIP相关癌与IDC相关癌具有相似的临床病理特征,包括术前前列腺特异性抗原、Gleason评分、前列腺外侵犯、精囊侵犯和淋巴结转移(n = 36,P>0.05)。总之,AIP与IDC具有相似的ERG/PTEN免疫表型,并且表现出相似的临床行为,因此当活检发现AIP时,需要立即重复活检,正如2016年最新版《世界卫生组织泌尿系统和男性生殖器官肿瘤分类》中所推荐的那样。